Saiid Zarrabian

Filings by Saiid Zarrabian span 3 companies, the busiest being La Jolla Pharmaceutical Co, TuHURA Biosciences, Inc./NV and Penwest Pharmaceuticals Co. The record holds 13 filings, for trades running from 30 June 2010 to 7 December 2021.

No open-market sale appears; the market trades are 6 purchases worth €79k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants. Since January 2021: 2 purchases and no sales on the market.

In size, the median ticket on the buying side is €5,729. Clusters matter here: 2 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 8 December 2021, reports an open-market purchase of €22k in TuHURA Biosciences, Inc./NV. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.